Skip to main content

Advertisement

SpringerLink
Log in

Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens for breast cancer

  • Letter to the editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H, Lyman GH (2014) Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens. Support Care Cancer 22:3275–3285

    Article  PubMed  Google Scholar 

  2. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of the EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8–32

    Article  CAS  PubMed  Google Scholar 

  3. National Comphrehensive Cancer Network (NCCN) (2013) Clinical practice guidelines in oncology: myeloid growth factors. Version 2. www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed 14 November 2014

  4. Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387

    Article  CAS  PubMed  Google Scholar 

  5. Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273–1283

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Lakhanpal R, Stuart-Harris R, Chan A et al (2013) Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required. Breast Cancer Manag 2:367–374

    Article  CAS  Google Scholar 

  7. Gilbar P, McPherson I, Sorour N, Sanmugarajah J, Francesconi A, McCaffrey E (2014) High incidence of febrile neutropenia seen following adjuvant chemotherapy with docetaxel and cyclophosphamide for early breast cancer. Breast Cancer Manag 3:9–11

    Article  CAS  Google Scholar 

  8. Gilbar P, McPherson I, Sorour N, Sanmugarajah J (2014) High incidence of febrile neutropenia following adjuvant breast chemotherapy with docetaxel, carboplatin and trastuzumab. Breast Cancer Manag 3:327–333

    Article  CAS  Google Scholar 

  9. Valero V, Forbes J, Pegram MD et al (2011) Multicenter Phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149–156

    Article  CAS  PubMed  Google Scholar 

Download references

Disclaimers

The authors have no funding or conflicts of interest to disclose.

Author information

Authors and Affiliations

  1. Cancer and Palliative Care Services, Toowoomba Hospital, Pechey Street, Toowoomba, QLD, 4350, Australia

    Peter Gilbar, Natacha Sorour & Ian McPherson

  2. School of Medicine, University of Queensland (Rural Clinical School), Toowoomba Hospital, Toowoomba, Australia

    Peter Gilbar

Authors
  1. Peter Gilbar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natacha Sorour
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ian McPherson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Gilbar.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gilbar, P., Sorour, N. & McPherson, I. Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens for breast cancer. Support Care Cancer 23, 619–620 (2015). https://doi.org/10.1007/s00520-015-2608-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-015-2608-x

Keywords

Search

Navigation